WNT1 and cardiac hypertrophy: Further, gene therapy through delivery of rAA9-mediated anti-miR-128 gene-alleviated TAC- or ISO-induced hypertrophic and dysfunctional response and declined Wnt1/β-catenin activation, suggesting miR-128 silencing inhibitory to Wnt1/β-catenin is required for protection from the progressive cardiac hypertrophy and heart failure.